[HTML][HTML] Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
D Bottomly, N Long, AR Schultz, SE Kurtz…�- Cancer�…, 2022 - pubmed.ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
[HTML][HTML] Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
D Bottomly, N Long, AR Schultz, SE Kurtz, CE Tognon…�- Cancer Cell, 2022 - Elsevier
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
[HTML][HTML] Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
D Bottomly, N Long, AR Schultz, SE Kurtz, CE Tognon…�- Cancer Cell, 2022 - cell.com
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
[HTML][HTML] Integrative Analysis of Drug Response and Clinical Outcome in Acute Myeloid Leukemia
D Bottomly, N Long, AR Schultz, SE Kurtz…�- Cancer cell, 2022 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
D Bottomly, N Long, AR Schultz, SE Kurtz…�- Cancer�…, 2022 - scholarship.miami.edu
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
D Bottomly, N Long, AR Schultz, S Kurtz…�- Cancer�…, 2022 - ohsu.elsevierpure.com
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
D Bottomly, N Long, AR Schultz, SE Kurtz, CE Tognon… - paper.sciencenet.cn
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
Integrative Analysis of Drug Response and Clinical Outcome in Acute Myeloid Leukemia
D Bottomly, N Long, AR Schultz, SE Kurtz, CE Tognon… - papers.ssrn.com
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
D Bottomly, N Long, AR Schultz, SE Kurtz…�- Cancer�…, 2022 - pure.johnshopkins.edu
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and�…